Can a diabetes drug protect kidneys in advanced disease?
NCT ID NCT05309785
First seen Mar 18, 2026 · Last updated May 07, 2026 · Updated 7 times
Summary
This study looks at whether canagliflozin, a drug used for diabetes, can safely reduce kidney damage in people with advanced chronic kidney disease (CKD), including those on dialysis. About 35 adults with stage 4 or 5 CKD will take the drug for up to 26 weeks. Researchers will measure changes in urine protein levels and drug exposure to see if it works and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESRD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
McGill University Health Center
Montreal, Quebec, Canada
Conditions
Explore the condition pages connected to this study.